Straits Times Index
3,297.55 -26.98 (-0.81%) S&P 500
5,431.60 -2.14 (-0.04%) Dow
38,589.16 -57.94 (-0.15%) Nasdaq
17,688.88 +21.28 (+0.12%) Bitcoin USD
66,721.02 +673.84 (+1.02%) CMC Crypto 200
1,388.72 -29.15 (-2.06%)
Delcath Systems Inc (DV3R.F)
| Previous close | 6.50 |
| Open | 6.80 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 6.80 - 7.00 |
| 52-week range | 2.18 - 7.35 |
| Volume | |
| Avg. volume | 18 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath’s Board of Directors
NEW YORK, May 28, 2024--Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024.
- GuruFocus.com
Delcath Systems Inc (DCTH) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...
Explore Delcath Systems Inc's robust Q1 2024 performance, featuring significant revenue growth, operational expansions, and strategic insights into future profitability.
PR NewswireDelcath Systems Reports First Quarter 2024 Results and Business Highlights
Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the first quarter ended March 31, 2024.
